NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 67 resultados LastUpdate Última actualización 17/04/2021 [15:06:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


CD47 blockade with parp inhibition for disease treatment

NºPublicación: AU2019336345A1 15/04/2021

Solicitante:

TRILLIUM THERAPEUTICS INC [CA]

CA_3111323_A1

Resumen de: AU2019336345A1

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.

traducir

BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE

NºPublicación: US2021107917A1 15/04/2021

Solicitante:

KURA ONCOLOGY INC [US]
UNIV MICHIGAN REGENTS [US]

CN_109640987_A

Resumen de: US2021107917A1

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

traducir

NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS

NºPublicación: US2021107941A1 15/04/2021

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

US_2020308225_A1

Resumen de: US2021107941A1

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

traducir

RADIOIMMUNOCONJUGATES IN COMBINATION WITH OTHER DRUGS AS TREATMENT AGAINST NHL

NºPublicación: US2021106703A1 15/04/2021

Solicitante:

NORDIC NANOVECTOR ASA [NO]

JP_2021504341_A

Resumen de: US2021106703A1

The present invention relates to a combination of radioimmunoconjugates and a protein or molecule capable of leading to progression of the cell cycle through the G2/M checkpoint, a protein or molecule capable of inhibiting progression through Mitosis, a protein or molecule which is a BCL2 inhibitor, or a protein or molecule which is a PARP inhibitor, for use as a medicament. The medicament may be against Non-Hodgkin's lymphoma (NHL).

traducir

METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS

NºPublicación: EP3801768A1 14/04/2021

Solicitante:

ACTUATE THERAPEUTICS INC [US]

CN_112351819_A

Resumen de: WO2019236703A1

Methods of treating malignant ly mphopr oli ferati ve disorders in a patient, comprising administering an effective amount of a GSK-3β inhibitor, for example 9-ING-41, are provided. Also provided are methods for treating malignant lymphoprohferative disorders comprising administering a (ϊ8Κ-3β inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.

traducir

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

NºPublicación: EP3805218A1 14/04/2021

Solicitante:

SYROS PHARMACEUTICALS INC [US]

AU_2021201536_A1

Resumen de: EP3805218A1

The present invention provides novel compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

traducir

METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA RELAPSE

NºPublicación: EP3802583A1 14/04/2021

Solicitante:

ONCOIMMUNE INC [US]
UNIV MARYLAND [US]

KR_20210018294_A

Resumen de: WO2019236474A1

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

traducir

SPECIFIC ANTI-CD38 ANTIBODIES FOR TREATING HUMAN CANCERS

NºPublicación: EP3805266A1 14/04/2021

Solicitante:

SANOFI SA [FR]

MA_44560_A1

Resumen de: EP3805266A1

The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38<+> cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

traducir

EZH2 INHIBITORS FOR TREATING LYMPHOMA

NºPublicación: AU2021201705A1 08/04/2021

Solicitante:

EPIZYME INC [US]

US_2019255060_A1

Resumen de: AU2021201705A1

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. See Figs. 1A and 1B. WO 2016/201328 PCT/US2016/037024 0) ui >~ V e ( )"") EV-d 4-11 4-J) C) C C) ) C) C) Cell L/ABG(vn) 0'0 RJi79-Zd ]

traducir

Regulator of nitrogen-containing heteroaromatic derivatives, preparation method therefor and use thereof

NºPublicación: AU2019357433A1 08/04/2021

Solicitante:

JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
SHANGHAI HANSOH BIOMEDICAL CO LTD

TW_202028183_A

Resumen de: AU2019357433A1

The present invention relates to a regulator of nitrogen-containing heteroaromatic derivatives, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer, wherein the definition of each substituent in the general formula (I) is the same as that in the description.

traducir

Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cell

NºPublicación: AU2019339870A1 08/04/2021

Solicitante:

GREEN CROSS LAB CELL CORP
MORPHOSYS AG

CA_3112689_PA

Resumen de: AU2019339870A1

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.

traducir

SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

NºPublicación: US2021101908A1 08/04/2021

Solicitante:

KURA ONCOLOGY INC [US]
UNIV MICHIGAN REGENTS [US]

JP_2019510004_A

Resumen de: US2021101908A1

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

traducir

SYSTEMS AND METHODS FOR AUTOMATED CLASSIFICATION OF SUBTYPING OF LEUKEMIA CELLS

NºPublicación: US2021102886A1 08/04/2021

Solicitante:

UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]
UNIV NAT TAIWAN [TW]

Resumen de: US2021102886A1

This application relates generally to automated systems and methods for classifying subtypes of leukemia cells and other applications therefrom.

traducir

CHIMERIC ANTIGEN RECEPTOR

NºPublicación: US2021101959A1 08/04/2021

Solicitante:

AUTOLUS LTD [GB]

JP_2019052190_A

Resumen de: US2021101959A1

The present invention provides a chimeric antigen recept- or (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.

traducir

IMMUNOMODULATORY IMIDE DRUGS AS ZETA-CHAIN-ASSOCIATED PROTEIN KINASE 70 (ZAP70) AGONISTS AND USES THEREOF

NºPublicación: WO2021067546A1 08/04/2021

Solicitante:

DANA FARBER CANCER INST INC [US]

Resumen de: WO2021067546A1

The present disclosure provides methods of treating a disease in a subject in need thereof (e.g., proliferative diseases (e.g., cancer (e.g., multiple myeloma))) comprising administering to a subject in need thereof an effective amount of an immunomodulatory drug (e.g., pomalidomide, thalidomide, lenalidomide, iberdomide). The disclosed IMiDs may increase the activity of a kinase (e.g., Zap-70). Also provided are kits comprising the disclosed IMiDs.

traducir

METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR TO RESPONSIVENESS TO DRUGS

NºPublicación: US2021102257A1 08/04/2021

Solicitante:

CELGENE CORP [US]

MX_2018003697_A

Resumen de: US2021102257A1

In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.

traducir

METHODS FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA

NºPublicación: WO2021064069A1 08/04/2021

Solicitante:

INST NAT SANTE RECH MED [FR]
CENTRE NAT RECH SCIENT [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV PARIS [FR]

Resumen de: WO2021064069A1

Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic virus type I (HTLV-I). The inventors performed an integrated genomic analysis of a retrospective cohort of 62 ATL patients mainly originating from Africa and the Caribbean area. In particular, they identified a subset of mutations in the TCR/NF-KB pathway (PLCG1, CARD11, PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, VAV1). Furthermore, the inventors investigated the effects of an anti-CD3 antibody (OKT3) exposure on 4 ATL samples including 2 cases harboring CARD 11 and PRKCB gain of function alterations and 2 cases without any TCR pathway mutation. The data suggest that ATL harboring TCR pathway mutations clearly responded to anti-CD3 (Fig. IB, red + OKT3) and died by apoptosis possibly by a mechanism resembling AICD. Importantly, these TCR-pathway/NFKB mutated patients also showed poorer outcome as compared to unmutated cases. Accordingly, the present invention relates to a method of treating adult T-cell leukemia/lymphoma (ATL) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD3 antibody.

traducir

N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

NºPublicación: WO2021066559A1 08/04/2021

Solicitante:

KAINOS MEDICINE INC [KR]

Resumen de: WO2021066559A1

N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.

traducir

COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROMES AND OTHER BLOOD DISEASES AND DISORDERS

NºPublicación: WO2021067914A1 08/04/2021

Solicitante:

UNIV COLUMBIA [US]

Resumen de: WO2021067914A1

The present disclosure provides for methods and compositions for preventing and treating myelodysplastic syndromes, acute myeloid leukemia, and other diseases and disorders of the blood, using a combination therapy including all-trans retinoic acid (ATRA) which inhibits or decreases β-catenin, and a ΤΟΡβ inhibitor.

traducir

PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND MDM2 INHIBITOR

NºPublicación: WO2021066443A1 08/04/2021

Solicitante:

HANMI PHARM IND CO LTD [KR]

Resumen de: WO2021066443A1

Provided are: a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing a therapeutically effective combination of an FMS-like tyrosine kinase-3 (FLT3) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof, and a murine double minute 2 (MDM2) inhibitor, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a method for treating acute myeloid leukemia using same.

traducir

2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS

NºPublicación: US2021101870A1 08/04/2021

Solicitante:

REVOLUTION MEDICINES INC [US]

Resumen de: US2021101870A1

The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.

traducir

METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA

NºPublicación: WO2021061874A2 01/04/2021

Solicitante:

HARVARD COLLEGE [US]
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: WO2021061874A2

The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject.

traducir

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

NºPublicación: WO2021061752A1 01/04/2021

Solicitante:

NEONC TECH INC [US]

Resumen de: WO2021061752A1

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).

traducir

USE OF DNMT INHIBITOR

NºPublicación: WO2021060341A1 01/04/2021

Solicitante:

OHARA PHARMACEUTICAL CO LTD [JP]
UNIV SAGA [JP]

Resumen de: WO2021060341A1

[Problem] As a substitute for an injection "Dacogen (registered trademark)" having been clinically used as a therapeutic drug for highly risky myelodysplastic syndrome and acute myeloid leukemia, to provide a compound as a therapeutic or prophylactic drug for TKI resistant CML, said compound having a high stability to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed in the body even by oral administration and, when taken into a nucleic acid biosynthesis route, exhibiting an effect of inhibiting DNA methyltransferase (DNMT). [Solution] A prophylactic and/or therapeutic agent for TKI resistant CML, said agent comprising a compound represented by formula (I) or a salt thereof. [In the formula, R1 and R2 each represent a hydrogen atom or a silyl group represented by formula (II) (wherein R3, R4 and R5 each represent an optionally substituted alkyl, aryl or arylalkyl group), provided that R1 and R2 do not represent a hydrogen atom at the same time.]

traducir

ANALYSIS METHODS FOR MULTIPLEX TISSUE IMAGING INCLUDING IMAGING MASS CYTOMETRY DATA

Nº publicación: WO2021062272A2 01/04/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]
UNIV SOUTHERN CALIFORNIA [US]

Resumen de: WO2021062272A2

The invention relates to methods for multiplex tissue imaging by methods such as imaging mass cytometry (IMC) and methods for analysis of imaging mass cytometry data. In various embodiments, methods are provided of cell-of-origin analysis and mutational analysis, coupled with spatial parameters derived from tumor clusters in the tumor microenvironment; which reveals signature marker profiles and therapeutic targets for treating cancers including diffuse large B cell lymphoma.

traducir

Página1 de 3 nextPage por página

punteroimgVolver